Rabeprazole + Amoxicillin + Clarithromycin

Finix HP is indicated for the eradication of H. pylori in active chronic gastric, duodenal and gastric ulcers.

Dosage & Administration

Each strip twice daily for 7 days. In case of severity, each strip twice daily for 14 days.
Geriatric patients: Elderly patients may suffer from asymptomatic renal and hepatic dysfunction. Care should be taken when administering to these patients.

Adverse reactions which were reported as possibly or probably related to treatment (<3%) in clinical trials when all three components of this therapy were given concomitantly are listed below and divided by body systems.
Digestive system
: Nausea, vomiting, diarrhoea, dark stools, dry mouth, glossitis, oral moniliasis, stomatitis, tongue discoloration
Musculoskeletal system
: Myalgia
Nervous System
: Confusion, headache, dizziness
Skin
: Skin reactions
Urogenital System
: Vaginitis, vaginal moniliasis.

Amoxicillin
is similar to penicillin in its bactericidal action against susceptible bacteria during the stage of active multiplication. It acts through the inhibition of cell wall biosynthesis that leads to the death of the bacteria.
Clarithromycin
acts by inhibiting microsomal protein synthesis in susceptible organisms mainly by binding to the donor site on the 50S subunit of the bacterial ribosome and preventing translocation to that site.
Rabeprazole
belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+,K+ ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion.